# Module 5: Treatment and Management of Soil Transmitted Diseases

## 5.1 Introduction to Treatment Strategies

### Overview
Treatment of Soil Transmitted Diseases (STH) involves:
- **Anthelmintic chemotherapy**
- **Supportive care**
- **Nutritional supplementation**
- **Surgical intervention** (when indicated)

### WHO Treatment Guidelines
- **Preventive chemotherapy**: Mass drug administration
- **Individual treatment**: Case management
- **Integrated approach**: Combined with WASH interventions

## 5.2 Anthelmintic Drugs

### Benzimidazoles

#### Albendazole
- **Mechanism**: Inhibits microtubule polymerization
- **Dosage**:
  - Adults: 400 mg single dose
  - Children: 200 mg single dose
  - Preschool children: 200 mg single dose
- **Efficacy**:
  - Ascaris: 95-100%
  - Trichuris: 30-90%
  - Hookworm: 70-95%
- **Side effects**: Mild, transient abdominal pain, nausea

#### Mebendazole
- **Mechanism**: Same as albendazole
- **Dosage**:
  - Adults: 500 mg single dose or 100 mg twice daily for 3 days
  - Children: 500 mg single dose or 100 mg twice daily for 3 days
- **Efficacy**: Similar to albendazole
- **Side effects**: Minimal, occasional diarrhea

#### Comparative Efficacy

| Parasite | Albendazole (400 mg) | Mebendazole (500 mg) |
|----------|---------------------|---------------------|
| **Ascaris** | 88-95% | 90-96% |
| **Trichuris** | 60-90% | 60-70% |
| **Hookworm** | 80-95% | 20-30% |

### Other Anthelmintics

#### Pyrantel Pamoate
- **Mechanism**: Neuromuscular blockade (depolarizing)
- **Dosage**: 10 mg/kg single dose (max 1g)
- **Efficacy**:
  - Ascaris: 85-95%
  - Hookworm: 50-90%
  - Trichuris: Limited efficacy
- **Advantages**: Safe in pregnancy, well-tolerated

#### Levamisole
- **Mechanism**: Nicotinic acetylcholine agonist
- **Dosage**: 2.5 mg/kg single dose
- **Efficacy**: Good against Ascaris, moderate against hookworm
- **Side effects**: Nausea, vomiting, mild neurological symptoms

## 5.3 Treatment Strategies

### WHO Recommended Treatment Approaches

#### Mass Drug Administration (MDA)
- **Target**: School-age children (5-14 years)
- **Frequency**: 1-2 times per year
- **Coverage**: ≥75% of target population
- **Drugs**: Albendazole or mebendazole

#### Targeted Treatment
- **High-risk groups**: Preschool children, pregnant women
- **Frequency**: Based on prevalence
- **Integration**: With vitamin A supplementation, immunization

#### Individual Treatment
- **Clinical cases**: Symptomatic patients
- **High intensity**: EPG >10,000
- **Complications**: Surgical emergencies

### Treatment Algorithms

#### Community Level Algorithm
1. **Screening**: Kato-Katz or clinical assessment
2. **Drug selection**: Based on prevalence and species
3. **Administration**: Single dose treatment
4. **Follow-up**: After 2-4 weeks

#### Hospital Level Algorithm
1. **Clinical assessment**: Severity evaluation
2. **Laboratory confirmation**: Egg quantification
3. **Comorbidity assessment**: Anemia, malnutrition
4. **Treatment planning**: Drug selection and supportive care
5. **Monitoring**: Response assessment

## 5.4 Management of Complications

### Severe Anemia Management
- **Assessment**: Hemoglobin <8 g/dL
- **Transfusion**: Packed red cells if Hb <7 g/dL
- **Iron supplementation**: 3-6 mg/kg/day elemental iron
- **Anthelmintic treatment**: After stabilization
- **Monitoring**: Weekly hemoglobin until normal

### Intestinal Obstruction (Ascaris)
- **Conservative management**:
  - Nil per oral
  - IV fluids
  - Nasogastric decompression
  - Anthelmintics after resolution
- **Surgical intervention**:
  - Complete obstruction
  - Peritonitis
  - Gangrene

### Rectal Prolapse (Trichuris)
- **Conservative**: Manual reduction, adhesive strapping
- **Surgical**: Prolapse ring application if recurrent
- **Anthelmintic**: After prolapse reduction

## 5.5 Special Populations

### Pregnant Women
- **First trimester**: Avoid anthelmintics if possible
- **Second/third trimester**: Treat if indicated
- **Drugs of choice**: Albendazole (after first trimester)
- **Monitoring**: Fetal growth, maternal anemia

### Lactating Mothers
- **Safety**: All WHO-recommended drugs safe
- **Treatment**: Standard single dose
- **Infant consideration**: No special precautions needed

### Children Under 2 Years
- **Treatment**: Recommended in endemic areas
- **Dosage**: Age-appropriate dosing
- **Monitoring**: Growth and development
- **Integration**: With immunization programs

### Immunocompromised Patients
- **HIV/AIDS**: Higher intensity infections
- **Treatment**: Standard protocols
- **Monitoring**: More frequent follow-up
- **ART interaction**: No significant interactions

## 5.6 Drug Resistance and Efficacy Monitoring

### Anthelmintic Resistance
- **Definition**: <95% cure rate or <90% egg reduction
- **Current status**: Emerging resistance to benzimidazoles
- **Geographic distribution**: Limited reports, mainly veterinary

### Resistance Detection Methods
- **Fecal egg count reduction test (FECRT)**:
  - Pre-treatment EPG
  - Post-treatment EPG (14 days)
  - Reduction <95% indicates resistance
- **In vitro assays**: Egg hatch assays
- **Molecular markers**: β-tubulin gene mutations

### Monitoring Protocols
- **Sentinel sites**: Regular efficacy monitoring
- **Baseline surveys**: Pre-MDA efficacy
- **Annual monitoring**: Treatment impact assessment
- **Investigation**: When efficacy <90%

## 5.7 Supportive Care and Nutrition

### Nutritional Supplementation
- **Iron therapy**:
  - Elemental iron 3-6 mg/kg/day
  - Duration: 3 months
  - Hookworm-associated anemia
- **Vitamin A**: 200,000 IU single dose (children)
- **Multivitamins**: In severe malnutrition
- **Protein supplementation**: Severe hypoalbuminemia

### Dietary Management
- **High protein diet**: Animal/plant proteins
- **Iron-rich foods**: Leafy vegetables, meat, fortified foods
- **Vitamin C**: Enhances iron absorption
- **Avoidance**: Tea, coffee with meals (inhibits iron absorption)

## 5.8 Surgical Management

### Indications for Surgery

#### Ascaris Complications
- **Intestinal obstruction**: Complete or strangulated
- **Biliary ascariasis**: With complications
- **Perforation**: With peritonitis
- **Appendicitis**: Worm-induced

#### Trichuris Complications
- **Rectal prolapse**: Recurrent, non-reducible
- **Intestinal perforation**: Rare
- **Toxic megacolon**: Emergency surgery

#### Hookworm Complications
- **Severe anemia**: With cardiac failure
- **Intestinal perforation**: Rare
- **Volvulus**: Secondary to anemia

### Surgical Techniques
- **Enterotomy**: Worm extraction
- **Resection anastomosis**: Gangrenous bowel
- **Cholecystectomy**: Biliary complications
- **Prolapse surgery**: Rectopexy for recurrent cases

## 5.9 Treatment Efficacy Assessment

### Cure Rate Calculation
- **Formula**: (Pre-treatment positive - Post-treatment positive) / Pre-treatment positive × 100
- **Timing**: 14-21 days post-treatment
- **Threshold**: >95% for drug efficacy

### Egg Reduction Rate (ERR)
- **Formula**: (Pre-treatment EPG - Post-treatment EPG) / Pre-treatment EPG × 100
- **Interpretation**:
  - Satisfactory: >90% reduction
  - Unsatisfactory: <90% reduction

### Monitoring Parameters
- **Clinical response**: Symptom improvement
- **Hematological**: Hemoglobin increase
- **Nutritional**: Weight gain, growth
- **Parasitological**: Egg count reduction

## 5.10 Integrated Management

### WASH Integration
- **Water**: Safe drinking water supply
- **Sanitation**: Latrine construction and use
- **Hygiene**: Hand washing promotion
- **Integration**: Combined with MDA programs

### Health Education
- **Community awareness**: Disease transmission
- **Behavioral change**: Hygiene practices
- **School programs**: Child-focused education
- **Mass media**: Radio, television campaigns

### Intersectoral Collaboration
- **Health sector**: Treatment and diagnosis
- **Education sector**: School-based programs
- **Water sector**: Infrastructure development
- **Agriculture**: Fertilizer management

## 5.11 Alternative and Complementary Therapies

### Traditional Medicine
- **Plant-based remedies**: Limited evidence
- **Monitoring**: Safety and efficacy studies needed
- **Integration**: With modern medicine

### Probiotics and Prebiotics
- **Gut microbiota**: Restoration after treatment
- **Evidence**: Limited clinical trials
- **Recommendation**: Not as alternative to anthelmintics

## 5.12 Pharmacovigilance

### Adverse Event Monitoring
- **Common events**: Abdominal pain, nausea, headache
- **Serious events**: Allergic reactions, seizures (rare)
- **Reporting**: National pharmacovigilance systems
- **Management**: Symptomatic treatment

### Drug Interactions
- **Cimetidine**: Increases albendazole levels
- **Dexamethasone**: Decreases albendazole efficacy
- **ART drugs**: No significant interactions
- **Antacids**: May reduce absorption

## 5.13 Treatment Costs and Accessibility

### Drug Costs
- **Albendazole**: $0.02-0.05 per treatment
- **Mebendazole**: $0.02-0.04 per treatment
- **Pyrantel**: $0.10-0.20 per treatment

### Program Costs
- **Delivery costs**: $0.20-0.50 per treatment
- **Training**: $0.05-0.10 per treatment
- **Monitoring**: $0.10-0.20 per treatment

### Accessibility Issues
- **Drug supply**: Procurement and distribution
- **Human resources**: Trained personnel
- **Infrastructure**: Storage and transportation
- **Community acceptance**: Cultural beliefs

## 5.14 Future Treatment Options

### New Drug Development
- **Emodepside**: Veterinary drug, human trials
- **Moxidectin**: Long-acting anthelmintic
- **Tribendimidine**: Broad-spectrum activity
- **Oxantel pamoate**: Trichuris-specific

### Drug Combinations
- **Albendazole + ivermectin**: Enhanced efficacy
- **Mebendazole + pyrantel**: Improved cure rates
- **Triple therapy**: For resistant infections

### Vaccines
- **Research stage**: Experimental vaccines
- **Target antigens**: ASP proteins, VAL proteins
- **Challenges**: Multiple species, antigenic variation

## 5.15 Summary and Key Points

### Essential Treatment Principles
1. **Single dose** treatment highly effective
2. **Mass drug administration** for control
3. **Integration** with nutrition and WASH
4. **Monitoring** essential for resistance detection

### Public Health Impact
- **Cost-effective** intervention
- **Rapid impact** on morbidity
- **Sustainable** with integrated approach
- **Scalable** to national programs

## 5.16 Assessment Questions

1. Compare the efficacy of different anthelmintic drugs against STH parasites.
2. Describe the WHO recommended treatment strategies for STH control.
3. Explain how to manage severe anemia in hookworm infection.
4. What are the current challenges in anthelmintic resistance?
5. How is treatment efficacy assessed in STH control programs?

## 5.17 References and Further Reading

1. WHO. (2017). Guideline: preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups.
2. Keiser, J., & Utzinger, J. (2008). Efficacy of current drugs against soil-transmitted helminth infections.
3. Albonico, M., et al. (2003). Monitoring drug efficacy and early detection of drug resistance in human soil-transmitted nematodes.
4. WHO. (2013). Assessing the efficacy of anthelminthic drugs against schistosomiasis and soil-transmitted helminthiases.
5. Vercruysse, J., et al. (2011). Is anthelmintic resistance a concern for the control of human soil-transmitted helminths?
